In brief: Select Vaccines, Psiron, Visiomed
Thursday, 21 April, 2005
Select Vaccines' (ASX:SLT) hepatitis E diagnostics kits have gained CE Mark approval for sale in the European Union. The company will sell the kits from June this year through its licencee, Genelabs
Psiron (ASX:PSX) has presented new data at a US medical conference confirming the anti-cancer effect in in vitro trials of its Coxsackievirus A21 virotherapy in cancer cell lines for breast, prostate and colon cancer and multiple myeloma.
Visiomed (ASX:VSG) subsidiary InfaMed has begun to sell its Funhaler children's asthma spacer device in Australian pharmacies.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
